Histogen Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2013-12-20: Form 8-K; Period of report 2013-12-20; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2013-12-03: Form 8-K; Period of report 2013-12-03; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2013-11-14: Form 8-K; Period of report 2013-11-14; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2013-10-02: Form 8-K; Period of report 2013-09-25; Description 1.02 Termination of a Material Definitive Agreement; Details 1.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2013-12-20 | 8-K | 2013-12-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 20, 2013, Marc Perret notified the board of directors (the “Board”) of Conatus Pharmaceuticals Inc. (the “Company”) that he would be resigning from the Board, effective as of December 31, 2013. | d648314d8k.htm |
| 2013-12-03 | 8-K | 2013-12-03 | 7.01 Regulation FD Disclosure | 7.01 On December 3, 2013, representatives of Conatus Pharmaceuticals Inc. (“Conatus”) will be attending meetings with investors, analysts and others in connection with the Piper Jaffray 25th Annual Healthcare Conference in New York, New York. | d637311d8k.htm |
| 2013-11-14 | 8-K | 2013-11-14 | 2.02 Results of Operations and Financial Condition | 2.02 On November 14, 2013, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter ended September 30, 2013. | d626968d8k.htm |
| 2013-10-02 | 8-K | 2013-09-25 | 1.02 Termination of a Material Definitive Agreement | 1.02 On September 25, 2013, Conatus Pharmaceuticals Inc. (“Conatus”) prepaid the outstanding advances under the loan and security agreement, dated as of July 3, 2013, by and among Conatus, Oxford Finance LLC (“Oxford”), as collateral agent, the lenders party thereto from time to time, including Silicon Valley Bank and Oxford in its capacity as a lender. | d607091d8k.htm |
| 2013-09-09 | 8-K | 2013-09-09 | 2.02 Results of Operations and Financial Condition | 2.02 On September 9, 2013, Conatus Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter ended June 30, 2013. | d595455d8k.htm |
| 2013-08-01 | 8-K | 2013-07-30 | 3.02 Unregistered Sales of Equity Securities; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 3.02 On July 30, 2013, Conatus Pharmaceuticals Inc. (the “Company”) issued 91,948 shares of its common stock (the “Conversion Shares”) to certain of its stockholders in connection with the completion of the initial public offering of shares of its common stock (the “IPO”). 5.03 On July 30, 2013, in connection with closing of the IPO, the Company filed an amended and restated certificate of incorporation (the “Charter”) with the Secretary of State of the State of Delaware. | d577904d8k.htm |